drugset / Trial / NCT02170896
Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
To assess the amount of BIBR 953 ZW in urine of 50 mg of BIBR 1048 bid over three days each administered as four experimental capsule formulations relative to drinking solution with and without coadministration of 40 mg pantoprazole.
Timeline
- Start
- 2001-10
- Primary completion
- 2001-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 50 mg | Oral |
| Subject | Pantoprazole | Other / unclassified | 40 mg | — |
Indications
No indication recorded.